



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 5, 2018

Cedric Francois, M.D., Ph.D  
President and Chief Executive Officer  
Apellis Pharmaceuticals, Inc.  
6400 Westwind Way, Suite A  
Crestwood, KY 40014

**Re: Apellis Pharmaceuticals, Inc.**  
**Draft Registration Statement on Form S-1**  
**Submitted April 3, 2018**  
**CIK No. 0001492422**

Dear Dr. Francois:

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Christine Westbrook at (202) 551-5019 with any questions.

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Stuart M. Falber, Esq.